Tier 2 — strong

INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN

Maryana I Prokosa
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2022 75(7):1653-1657

Bibliography

PubMed
PMID 35962675
DOI
10.36740/WLek202207107
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignComparative adjunct-treatment hypertension study
ModelHuman intervention research
Sample72 patients with stage 2 hypertension
InterventionCorvitin or Quertin added to ramipril/amlodipine versus standard therapy
DurationDose and duration not stated in the indexed abstract
EndpointsLipid measurements; Inflammatory measures

What the study showed, in plain terms

Published in 2022, this source examined cardiovascular and metabolic health. Design: Comparative adjunct-treatment hypertension study. Sample/model: 72 patients with stage 2 hypertension. The exposure or intervention was Corvitin or Quertin added to ramipril/amlodipine versus standard therapy. Follow-up or treatment period: Dose and duration not stated in the indexed abstract.

Selected inflammatory and lipid measures changed more in the adjunct group according to the authors.

Randomization, masking, routes, and clinical event outcomes are insufficiently reported. Biomarker results do not demonstrate reduced complication rates.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected inflammatory and lipid measures changed more in the adjunct group according to the authors.
  • The recorded outcome domains were Lipid measurements; Inflammatory measures.
  • The result applies to the tested exposure: Corvitin or Quertin added to ramipril/amlodipine versus standard therapy; Dose and duration not stated in the indexed abstract.

What this study can and cannot tell us

  • Randomization, masking, routes, and clinical event outcomes are insufficiently reported. Biomarker results do not demonstrate reduced complication rates.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015
Tier 2
Hypocholesterolemic Efficacy of Quercetin Rich Onion Juice in Healthy Mild Hypercholesterolemic Adults: A Pilot Study
Tsong-Ming Lu et al. · Plant foods for human nutrition (Dordrecht, Netherlands) · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology